Assessing the use of retrospective databases in conducting economic evaluations of drugs : the case of asthma
(2004) In PharmacoEconomics 22(12). p.771-791- Abstract
- When evaluating drug substances, the traditional clinical study setting does not allow scope for observing real-life behaviour since all alternative actions are determined beforehand. However, a study based on prospective or retrospective databases containing real-life data can examine how patients and physicians behave in a real-world setting and can investigate the relationship between the introduction of a drug and the amount of healthcare used in actual practice.
We reviewed the quality and potential policy application of published retrospective database studies in which an economic evaluation of the use of drugs in asthma was conducted. A search in literature databases found 16 such studies, which were reviewed and... (More) - When evaluating drug substances, the traditional clinical study setting does not allow scope for observing real-life behaviour since all alternative actions are determined beforehand. However, a study based on prospective or retrospective databases containing real-life data can examine how patients and physicians behave in a real-world setting and can investigate the relationship between the introduction of a drug and the amount of healthcare used in actual practice.
We reviewed the quality and potential policy application of published retrospective database studies in which an economic evaluation of the use of drugs in asthma was conducted. A search in literature databases found 16 such studies, which were reviewed and evaluated according to a published checklist. No article fulfilled all the criteria for a ‘good’ economic evaluation. The results of many of the evaluations may be informative, but not transparent enough to deliver policy conclusions. This may limit the use of the currently published retrospective database studies as a base for policy decision, compared with randomised controlled trials, despite the additional value of these database analyses when well conducted. A greater transparency when presenting material and results is therefore called for, to increase the usefulness of database studies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/126858
- author
- Berggren, Fredrik LU
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PharmacoEconomics
- volume
- 22
- issue
- 12
- pages
- 771 - 791
- publisher
- Adis International
- external identifiers
-
- pmid:15294011
- wos:000223645900002
- scopus:4344617872
- ISSN
- 1179-2027
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Lund University Centre for Health Economics (LUCHE) (016630120), Division of Health Economics and Forensic Medicine (Closed 2012) (013040050)
- id
- f94177bb-0382-4061-9d75-8f86c8d35735 (old id 126858)
- alternative location
- http://www.ingentaconnect.com/content/adis/pec/2004/00000022/00000012/art00002
- date added to LUP
- 2016-04-01 15:47:00
- date last changed
- 2022-02-05 02:59:41
@article{f94177bb-0382-4061-9d75-8f86c8d35735,
abstract = {{When evaluating drug substances, the traditional clinical study setting does not allow scope for observing real-life behaviour since all alternative actions are determined beforehand. However, a study based on prospective or retrospective databases containing real-life data can examine how patients and physicians behave in a real-world setting and can investigate the relationship between the introduction of a drug and the amount of healthcare used in actual practice.<br/><br>
<br/><br>
We reviewed the quality and potential policy application of published retrospective database studies in which an economic evaluation of the use of drugs in asthma was conducted. A search in literature databases found 16 such studies, which were reviewed and evaluated according to a published checklist. No article fulfilled all the criteria for a ‘good’ economic evaluation. The results of many of the evaluations may be informative, but not transparent enough to deliver policy conclusions. This may limit the use of the currently published retrospective database studies as a base for policy decision, compared with randomised controlled trials, despite the additional value of these database analyses when well conducted. A greater transparency when presenting material and results is therefore called for, to increase the usefulness of database studies.}},
author = {{Berggren, Fredrik}},
issn = {{1179-2027}},
language = {{eng}},
number = {{12}},
pages = {{771--791}},
publisher = {{Adis International}},
series = {{PharmacoEconomics}},
title = {{Assessing the use of retrospective databases in conducting economic evaluations of drugs : the case of asthma}},
url = {{http://www.ingentaconnect.com/content/adis/pec/2004/00000022/00000012/art00002}},
volume = {{22}},
year = {{2004}},
}